Ivan Jelas

430 total citations
22 papers, 200 citations indexed

About

Ivan Jelas is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Ivan Jelas has authored 22 papers receiving a total of 200 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 9 papers in Cancer Research and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Ivan Jelas's work include Colorectal Cancer Treatments and Studies (12 papers), Cancer Genomics and Diagnostics (9 papers) and Genetic factors in colorectal cancer (5 papers). Ivan Jelas is often cited by papers focused on Colorectal Cancer Treatments and Studies (12 papers), Cancer Genomics and Diagnostics (9 papers) and Genetic factors in colorectal cancer (5 papers). Ivan Jelas collaborates with scholars based in Germany, Austria and United States. Ivan Jelas's co-authors include Sebastian Stintzing, Jörg Trojan, Melanie Demes, Oliver Haase, Paul K. Ziegler, Christine Koch, Franziska Eckert, Wolfgang Strittmatter, Ulrich Keilholz and Stephen D. Gillies and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and International Journal of Cancer.

In The Last Decade

Ivan Jelas

21 papers receiving 197 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ivan Jelas Germany 8 134 44 43 38 34 22 200
Zorka Inić Serbia 5 92 0.7× 24 0.5× 55 1.3× 69 1.8× 13 0.4× 16 183
Laura Matteucci Italy 6 141 1.1× 58 1.3× 69 1.6× 78 2.1× 19 0.6× 15 272
Niko Kemi Finland 10 134 1.0× 22 0.5× 57 1.3× 62 1.6× 51 1.5× 14 296
Changyuan Guo China 9 191 1.4× 25 0.6× 41 1.0× 91 2.4× 33 1.0× 36 292
Sofia Westbom-Fremer Sweden 7 187 1.4× 24 0.5× 56 1.3× 56 1.5× 68 2.0× 12 299
Eric Walk United States 8 140 1.0× 26 0.6× 99 2.3× 53 1.4× 17 0.5× 10 234
Maria Passhak Israel 6 153 1.1× 16 0.4× 16 0.4× 25 0.7× 66 1.9× 9 182
Clarissa Filorizzo Italy 9 110 0.8× 66 1.5× 110 2.6× 61 1.6× 21 0.6× 16 294
Fabien Gaire Germany 5 133 1.0× 20 0.5× 88 2.0× 38 1.0× 21 0.6× 11 200
Hazem Khout United Kingdom 9 108 0.8× 38 0.9× 43 1.0× 85 2.2× 29 0.9× 21 222

Countries citing papers authored by Ivan Jelas

Since Specialization
Citations

This map shows the geographic impact of Ivan Jelas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ivan Jelas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ivan Jelas more than expected).

Fields of papers citing papers by Ivan Jelas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ivan Jelas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ivan Jelas. The network helps show where Ivan Jelas may publish in the future.

Co-authorship network of co-authors of Ivan Jelas

This figure shows the co-authorship network connecting the top 25 collaborators of Ivan Jelas. A scholar is included among the top collaborators of Ivan Jelas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ivan Jelas. Ivan Jelas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Modest, Dominik Paul, Volker Heinemann, Stefan Angermeier, et al.. (2024). Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116). Journal of Cancer Research and Clinical Oncology. 150(7). 332–332. 3 indexed citations
2.
Pankow, Anne, Udo Schneider, Katharina Ziegeler, et al.. (2024). VEXAS and Myelodysplastic Syndrome: An Interdisciplinary Challenge. Journal of Clinical Medicine. 13(4). 1049–1049. 4 indexed citations
3.
4.
Rieke, Damian, Manuela Benary, Peter Horak, et al.. (2023). Tumor mutational burden as a predictive biomarker for molecularly matched therapy in two independent pan-cancer cohorts.. Journal of Clinical Oncology. 41(16_suppl). 3066–3066. 1 indexed citations
5.
Benary, Manuela, Peter Horak, Mario Lamping, et al.. (2023). Tumour mutational burden and survival with molecularly matched therapy. European Journal of Cancer. 190. 112925–112925. 1 indexed citations
6.
Fischer, Laura, Sebastian Stintzing, Volker Heinemann, et al.. (2022). Liquid Biopsy in Colorectal Cancer: Quo Vadis? Implementation of Liquid Biopsies in Routine Clinical Patient Care in Two German Comprehensive Cancer Centers. Frontiers in Oncology. 12. 870411–870411. 2 indexed citations
7.
Kurreck, Annika, Volker Heinemann, Ludwig Fischer von Weikersthal, et al.. (2022). Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy—Analysis of the Phase 3 XELAVIRI Trial. Frontiers in Oncology. 12. 751453–751453. 2 indexed citations
8.
Rieke, Damian, Peter Horak, Mario Lamping, et al.. (2022). Feasibility and outcome of reproducible clinical interpretation of high-dimensional molecular data: a comparison of two molecular tumor boards. BMC Medicine. 20(1). 367–367. 12 indexed citations
9.
Heinemann, Volker, Michael Geißler, Ludwig Fischer von Weikersthal, et al.. (2022). Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy. Cancers. 14(3). 526–526. 4 indexed citations
10.
Trojan, Jörg, Sebastian Stintzing, Oliver Haase, et al.. (2021). Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer. The Oncologist. 26(12). e2110–e2114. 37 indexed citations
11.
12.
Stahler, Arndt, Volker Heinemann, Julian Walter Holch, et al.. (2021). Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE‐3). International Journal of Cancer. 149(11). 1935–1943. 1 indexed citations
13.
Osumi, Hiroki, Loredana Vecchione, Ulrich Keilholz, et al.. (2021). NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?—Case series and review of the literature. European Journal of Cancer. 153. 86–95. 19 indexed citations
14.
Leyvraz, Serge, Mieke Schutte, Torsten Keßler, et al.. (2020). 1142P Treatment of metastatic uveal melanoma (mUM) through genomic profiling. Annals of Oncology. 31. S764–S764.
15.
Stahler, Arndt, Volker Heinemann, Ingrid Ricard, et al.. (2020). Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials. Journal of Cancer Research and Clinical Oncology. 146(8). 2077–2087. 9 indexed citations
16.
McSkane, Michelle, Sebastian Stintzing, Volker Heinemann, et al.. (2018). Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study. Clinical Colorectal Cancer. 17(3). 215–222.e3. 4 indexed citations
17.
Holch, Julian Walter, Ingrid Ricard, Sebastian Stintzing, et al.. (2018). Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). European Journal of Cancer. 106. 115–125. 16 indexed citations
18.
Eckert, Franziska, Ivan Jelas, Stephan M. Huber, et al.. (2017). Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects in vivo. OncoImmunology. 6(6). e1323161–e1323161. 41 indexed citations
19.
Heitkamp, Hans‐Christian & Ivan Jelas. (2012). Körperliche Aktivität zur Primärprävention des Prostatakarzinoms. Der Urologe. 51(4). 527–532. 4 indexed citations
20.
Heitkamp, Hans‐Christian & Ivan Jelas. (2012). Epidemiologische Evidenz zur Prävention des Prostatakarzinoms durch körperliche Aktivität. Wiener Medizinische Wochenschrift. 162(23-24). 533–540. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zorka Inić Breakdown of academic impact, for papers by Laura Matteucci Breakdown of academic impact, for papers by Niko Kemi Breakdown of academic impact, for papers by Changyuan Guo Breakdown of academic impact, for papers by Sofia Westbom-Fremer Breakdown of academic impact, for papers by Eric Walk Breakdown of academic impact, for papers by Maria Passhak Breakdown of academic impact, for papers by Clarissa Filorizzo Breakdown of academic impact, for papers by Fabien Gaire Breakdown of academic impact, for papers by Hazem Khout
Rankless by CCL
2026